INTRODUCTION

Late ocular complications of sulfur mustard gas (MG) are very common among intoxicated individuals. Ocular toxicity of MG often manifests as dry eye and decreased tear meniscus. Subjects who were exposed to MG are at risk for dry eye disease due to the toxic effects of the agent. The most frequent destructive ocular complications of MG injury include chronic blepharitis, increased tear meniscus, limbal ischemia and conjunctival vascular abnormalities.

Susceptibility of the eyes to the toxic effects of MG is due to moistness of the ocular surface that allows rapid cyclization and activation of the agent, in addition to the high turnover and metabolic rate of corneal epithelial cells that increase their sensitivity to the lipophilic sulfur mustard trapped into the oily tear layer. The most frequent destructive ocular complications of MG injury include chronic blepharitis, decreased tear meniscus, limbal ischemia and conjunctival vascular abnormalities.

Correspondence to:
Yunes Panahi, Pharm.D, PhD. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Molla-Sadra Street, Tehran 19945, Iran.
E-mail: yunespanahi@yahoo.com
Received: 15-07-2013 Accepted: 18-01-2014

Access this article online

Quick Response Code: [QR Code]
Website: www.jovr.org
DOI: 10.4103/2008-322X.150803
persistent leading to corneal degeneration, or progress in a silent manner to severe ocular lesions.\[9\] While the pathophysiology of MG-induced keratitis remains obscure, an autoimmune reaction to corneal antigens has been suggested to play a central role in the development of this disease and causes severe limbal and corneal damage.\[7,9\]

Although various strategies are employed in the treatment and management of dry eye disease, currently available medications have limited efficacy in controlling the symptoms, especially in cases secondary to sulfur mustard (SM) exposure.\[10\] Hence, there is an urgent demand for novel therapeutic approaches in patients suffering from late ocular complications of SM. Recent studies have suggested a key role for an underlying inflammatory component in the pathogenesis of dry eye disease. This has led to the use of many anti-inflammatory-based therapies, such as short-term corticosteroids and long-term cyclosporine, to improve the efficacy of treatment in these patients.\[11,12\] Thus far, several lines of evidence have favored the effectiveness of topical cyclosporine A (tCsA) in the treatment of dry eye disease due to varying etiologies.\[13-17\] However, tCsA has not yet been tested in patients with late ocular complications of MG. The present study was undertaken to investigate the effects of tCsA in a group of MG-exposed patients suffering from severe dry eye disease.

**METHODS**

This prospective interventional case series included 36 MG-exposed male veterans suffering from symptoms of dry eye disease despite receiving artificial tear and punctal plugs. Inclusion criteria were ocular surface disease index (OSDI) score of ≥ 0.25 and Schirmer’s test (with anesthesia) <10 mm. All subjects underwent a thorough ocular examination including slit lamp biomicroscopy and visual acuity measurement using a logMAR chart (at 3 m testing distance). For each patient, only the more severely affected eye was included in the study. Exclusion criteria were the presence of active ocular infection, history of ocular surgery within the past 3 months, and a history of hypersensitivity to cyclosporine A. Individuals with any systemic diseases that may cause dry eye, such as diabetes mellitus, rheumatologic disorders and Sjögren’s syndrome were also excluded. The Ethics Committee at Baqiyatallah University of Medical Sciences approved the study protocol and written informed consent was obtained from all participants.

All participants were asked to stop using any previous topical medication. One drop of tCsA 0.05% (Restasis, Allergan Inc, Irvine, CA, USA) twice daily and one drop of preservative-free artificial tear (Artelac Advanced, Bausch and Lomb GmbH, Germany) every 6 hours were prescribed for each eye for a period of 3 months. Patients were encouraged to continue their medication and were advised to report any adverse effect during the follow-up period. Participants were informed that they might experience a burning sensation during the initial weeks of therapy. During the study period, patients were contacted every 3 weeks to assure their compliance with the medication and lack of adverse effects. After 3 months, all patients were re-examined using the same tests as the first visit.

Assessment of dry eye severity was performed at baseline and at the end of the study using tear osmolarity assay, OSDI, Schirmer’s test and tear break-up time (TBUT). Ocular surface staining with rose bengal or fluorescein was not performed in this study. The reason is that apart from the subjective nature of staining results, many patients with MG-induced keratitis have varying degrees of limbal stem cell deficiency which can affect the staining result independent of dry eye disease. Therefore, staining results may not be reliable in patients with MG-induced dry eye.

**Tear Osmolarity Measurement**

Patients were asked not to instill any drop in their eyes at least 1 hour prior to the test. Measurement of tear osmolarity was performed using an automated device (TearLab Osmolarity System, TearLab Corp., San Diego, CA, USA). This device can determine tear osmolarity with sample volumes as low as 50 nL with no need for additional calibration of the instrument as a coefficient of variation of 1.5% and analytical standard variation of ± 5.0 mOsmol/L allows performing the test just once with a high level of validity.

**Ocular Surface Disease Index**

A Persian translation of OSDI was applied which consists of 12 questions measuring the severity of dry eye symptoms. The OSDI score was calculated using methods described previously.\[18\]

**Schirmer’s Test**

To determine the Schirmer’s score, a standard Schirmer’s test strip was placed in the temporal third of the lower eyelid for 5 minutes and the length of the wet part was measured in millimeters. Prior to the test, one drop of proparacaine (Alcaine, Alcon Laboratories, TX, USA) was instilled in the eyes to measure basic tear secretion.

**Tear Break-Up Time Test**

To conduct the TBUT test, a fluorescein strip moistened with a drop of saline solution was placed on the inferior palpebral conjunctiva. The elapsed time before the initial break-up of tear film was counted in seconds. The test was repeated three times and the mean was reported as TBUT.
Statistical Analysis
Statistical analysis was performed using SPSS software version 18 (SPSS, Inc., Chicago, IL, USA). Given the normal distribution of data, paired-samples t-test was used for pre-and post-treatment comparisons. Bivariate associations between baseline and post-treatment values of the evaluated parameters as well as their changes during the course of the study were assessed using Pearson’s (in case of normally distributed data) or Spearman’s (in case of non-normally distributed data) correlation coefficients. P < 0.05 were considered as statistically significant.

RESULTS
A total of 36 eyes from 36 patients with mean age of 47.1 ± 6.5 years were included in this study. Two patients (5.6%) failed to complete the treatment period with tCsA. Reasons for drop-out were respiratory complications due to MG exposure which made it impossible to continue the study in one case and severe burning sensation and blurred vision after instillation of tCsA in another patient. These two cases were excluded from statistical analysis. Mean time from exposure to MG was 26.5 ± 0.7 years. All subjects were previously using preservative-free artificial tears for treatment of dry eye and 23 (63.9%) of them had undergone punctal plugging.

The most common symptom was blurred vision (83.3%) followed by ocular itching (72.2%). Slit lamp examination of the conjunctiva and cornea revealed abnormal findings such as corneal opacity in 13 (36.1%) cases, limbal ischemia affecting at least one-third of the limbus in 11 (30.1%) cases, and corneal vascularization in 10 (27.7%) cases.

Figure 1 shows the outcome measures before and after treatment. Best corrected visual acuity improved from 0.5 ± 0.2 LogMAR at baseline to 0.4 ± 0.2 LogMAR at the end of the study (P = 0.001). Mean OSDI score was 47.5 ± 7.2 at baseline and 42.7 ± 7.1 at the end of study (P < 0.001). There was a significant increase in Schirmer test scores from baseline (4.6 ± 1.3 mm) to the end of the study (5.0 ± 1.3 mm) (P < 0.001). tCsA therapy was associated with a significant decrease in tear osmolarity (from 301.7 ± 11.5–286.3 ± 7.9 mOsmol/L, P < 0.001), and a significant increase in TBUT (from 1.9 ± 1.4–2.7 ± 1.5 s, P < 0.001).

Overall, the majority of patients experienced improved symptoms associated with each evaluated efficacy measure. The proportion of patients with an improved score in Schirmer’s test, visual acuity and TBUT at the end of the study were 61.8%, 35.3% and 50%, respectively. The proportion of patients with an increased score in Schirmer’s test, visual acuity and TBUT at the end of the study were 61.8%, 35.3% and 50%, respectively. Also, the majority of patients (85.3%) had improved symptoms.
decreased tear osmolarity and OSDI score at the end of study as compared to baseline [Figure 2].

DISCUSSION

The morbidity associated with chronic complications of MG injury in different organs of the body necessitates attempts to find effective therapies to control the symptoms and correct the underlying biochemical imbalances following intoxication. The present study aimed to investigate the efficacy of tCsA 0.05% for treatment of severe dry eye in a group of veterans suffering from late ocular complications due to MG exposure. Our primary efficacy measure was the change in tear osmolarity as the most specific and accurate test for monitoring treatment efficacy. There is compelling evidence supporting that tear osmolarity has the highest correlation with the severity of dry eye disease. Tear film hyperosmolarity has been shown to play a critical role in the pathophysiology of aqueous tear deficiency and evaporative dry eye, and is directly connected to the etiology of disease manifestations.

In this study, all patients had previous history of treatment with preservative-free artificial tears. After 3 months of tCsA 0.05% (twice daily) treatment plus preservative-free artificial tears (four times daily), all subjective (OSDI score) and objective (Schirmer score, TBUT, tear osmolarity) parameters used for assessing dry eye improved significantly. As a late complication of exposure to MG, severe dry eye is common among exposed individuals and affects their quality of life. Two important elements in the pathogenesis of dry eye disease are eyelid inflammation and loss of conjunctival goblet cells, both leading to tear film instability and decreased tear meniscus.

Several studies have supported the efficacy of tCsA in improving signs and symptoms in different stages of dry eye disease. Nevertheless, to the best of our knowledge, no study has yet been conducted on patients with MG-induced disease. Stevenson et al showed the efficacy of tCsA at different concentrations in decreasing rose bengal staining, superficial punctuate keratitis, and symptoms of ocular discomfort in patients with moderate to severe keratoconjunctivitis sicca. They reported that the 0.05% concentration is associated with the highest rate of improvement. Sall et al compared treatment with tCsA 0.05%, 0.1%, or vehicle twice daily in 877 patients with moderate to severe dry eye. They found that both objective (corneal fluorescein staining and Schirmer’s values) and subjective measures of dry eye significantly improved in patients treated with tCsA (0.05 or 0.1%) as compared to those treated with vehicle. Perry et al also reported that tCsA is effective in all stages of dry eye disease, with most improvement of symptoms in mild stages and greatest alleviation of signs in severe stages. There is also evidence indicating that tCsA is effective in increasing goblet cell density in patients with dry eye disease. In a study by Moon et al, cyclosporine was found to be more effective in improving objective parameters of dry eye such as TBUT and goblet cell density than artificial tears. Also, the results of a trial by Pflugfelder et al revealed that cyclosporine emulsion, but not artificial tears, was effective in increasing goblet cell density in patients with dry eye. The use of tCsA for the treatment of dry eye has also been evaluated in different situations associated with this syndrome i.e., in patients undergoing LASIK or in patients with dry eye associated with graft versus host disease after stem cell transplantation.

Objective measurement of the effectiveness of an applied medication on dry eye has always been a great challenge, as many of the tests do not reflect the patients’ symptoms. In many of these methods such as Schirmer’s test or rose bengal staining, physical endpoints are used which reflect end-stage disease and have low positive predictive values (PPV). Researchers have shown that tear osmolarity is a test with the highest PPV and the most accurate one for diagnosis as well as follow-up of dry eye disease. The automated TearLab osmolarity system that was employed in the current study is an easy-to-use system which requires a very small amount (about 50 nL) of tear and can appropriately address concerns about effectiveness and rapidity of tear osmolarity measurement. It is well known that tear hyperosmolarity plays an important role in progression of inflammation and corneal epithelial damage in dry eye conditions by activating an inflammatory cascade. Hence, change in tear osmolarity is an important underlying factor that, along with ocular inflammation, is responsible for symptoms of the disease.

The main limitation of the present study was lack of any control group receiving artificial tears alone. In addition, although the participants were within the same age range and had a comparable time interval since exposure to MG, they were not completely homogeneous in terms of the frequency of different ocular abnormalities.

Figure 2. Proportion of subjects with improved stable or worsened score for each efficacy measure. OSDI, ocular surface disease index; TBUT, tear break-up time.
such as limbal ischemia, corneal opacity and corneal vascularization at baseline. It may also be argued that concurrent administration of artificial tears with tCsA is responsible, at least in part, for the favorable effects that were observed in this study. However, it must be taken into account that all enrolled patients had been unresponsive to artificial tear treatment and sought additional medications. Therefore, it is less likely that improvement in signs and symptoms were related to the use of artificial tear.

Finally, it must be noted that although the efficacy measures in this study were significantly improved by tCsA, the effect size was generally small and thus may not be clinically significant. Nevertheless, it is plausible to obtain clinically relevant effects after longer durations of treatment.

In summary, our study showed that tCsA 0.05% is effective in reducing tear osmolarity as well as improving symptoms in patients suffering from MG-induced dry eye disease. Given the role of tear hyperosmolarity as a major determinant of the progression and severity of dry eye disease,[44] and a high frequency of chronic ocular complications in MG-exposed individuals, it is recommended that tCsA 0.05% be considered as a potential treatment for reduction of symptoms and improvement of quality of life. The interesting results of the present pilot study on the efficacy of tCsA in decreasing MG-induced dry eye symptoms generates the basis for conducting future large-scale randomized controlled trials.

ACKNOWLEDGEMENTS

The authors would also like to thank all the subjects who participated in this study. Mostafa Mafi wishes to thank the National Elite Foundation of Iran for its support. Results of this study have been partly presented in the ISOPT Clinical Congress (7–10 March 2013, Paris, France).

REFERENCES

1. Solberg Y, Alcalay M, Belkin M. Ocular injury by mustard gas. Suro Ophthalmol 1997;41:461-466.
2. Safarinejad MR, Moosavi SA, Montazeri B. Ocular injuries caused by mustard gas: Diagnosis, treatment, and medical defense. Mil Med 2001;166:67-70.
3. Etezad-Razavi M, Mahmoudi M, Hefazi M, Balali-Mood M. Delayed ocular complications of mustard gas poisoning and the relationship with respiratory and cutaneous complications. Clin Experiment Ophthalmol 2006;34:342-346.
4. Baradaran-Rafiz A, Eslami M, Tseng SC. Sulfur mustard-induced ocular surface disorders. Ocul Surf 2011;9:163-178.
5. Javadi MA, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, et al. Chronic and delayed-onset mustard gas keratitis: Report of 48 patients and review of literature. Ophthalmology 2005;112:617-625.
6. Mertzianis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, et al. The relative burden of dry eye in patients’ lives: Comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 2005;46:46-50.
7. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop 2007. Ocul Surf 2007;5:163-178.
8. Kadar T, Turetz J, Fishbine E, Sahar R, Chapman S, Amir A. Characterization of acute and delayed ocular lesions induced by sulfur mustard in rabbits. Curr Eye Res 2001;22:42-53.
9. Jampol LM, Axelrod A, Tessler H. Pathways of the eye’s response to topical nitrogen mustard. Invest Ophthalmol 1976;15:486-489.
10. Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate-to-severe dry eye: Results of a physician survey. Eye Contact Lens 2010;36:33-38.
11. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pfughfelder SC. The pathology of dry eye: The interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-589.
12. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-974.
13. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-639.
14. Salib GM, McDonald MB, Smoak M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32:772-778.
15. Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M, et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 2008;41:293-302.
16. Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpp RN, Greenman HE, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008;126:1046-1050.
17. Byun YS, Rho CR, Cho K, Choi JA, Na KS, Joo CK. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: A prospective, multicenter, open-label, surveillance study. Korean J Ophthalmol 2011;25:369-374.
18. Schifftman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000;118:615-621.
19. Panahi Y, Davoudi SM, Beiraghdar F, Amiri M, Saadat A, Marzony ET, et al. Serum levels of interleukins 2, 4, 6, and 10 in veterans with chronic sulfur mustard-induced pruritis: A cross-sectional study. Skinmed 2013;11:205-209.
20. Panahi Y, Davoudi SM, Beiraghdar F, Saadat A, Sahebkar A. Relationship between levels of IFNγ, TNFα, and TGF-β and pruritis in sulfur mustard-exposed veterans. J Immunotoxicol 2013;10:173-177.
21. Panahi Y, Tabaryzadeh ES, Davoudi SM, Sahebkar A, Ranjar R. Investigation of serum substance P status in patients with chronic pruritic skin lesions due to sulfur mustard: A cross-sectional study. Cutan Ocul Toxicol 2013;32:4-8.
22. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012;49:580-588.
23. Panahi Y, Sahebkar A, Amiri M, Davoudi SM, Beiraghdar F, Hoseininejad SL, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: Results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 2012;108:1272-1279.
24. Sahebkar A. Baicalin as a potentially promising drug for the management of sulfur mustard induced cutaneous complications: A review of molecular mechanisms. Cutan Ocul Toxicol 2012;31:226-234.
25. Panahi Y, Sarayani A, Beiraghdar F, Amiri M, Davoudi SM, Sahebkar A. Management of sulfur mustard-induced chronic pruritus: A review of clinical trials. Cutan Ocul Toxicol 2012;31:220-225.
26. Panahi Y, Eftekhar Milani A, Sahebkar A, Naderi M, Babaei M, Beiraghdar F, et al. Tear total protein analysis in patients with late sulfur mustard-induced ocular complications: A cross-sectional study. Cutan Ocul Toxicol 2012;31:104-110.
27. Panahi Y, Davoudi SM, Sahebkar A, Beiraghdar F, Dadjo Y, Feizi I, et al. Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: A randomized double-blind clinical trial. Cutan Ocul Toxicol 2012;31:95-103.
28. Panahi Y, Sahebkar A, Davoudi SM, Amiri M, Beiraghdar F. Efficacy and safety of immunotherapy with interferon-gamma in the management of chronic sulfur mustard-induced cutaneous complications: Comparison with topical betamethasone 1%. ScientificWorldJournal 2012;2012:285274.
29. Panahi Y, Ghanei M, Vaheidi E, Ghazvini A, Parvin S, Madanchi N, et al. Effect of recombinant human IFNγ in the treatment of chronic pulmonary complications due to sulfur mustard intoxication. J Immunotoxicol 2014;11:72-77.
30. Liu H, Begley C, Chen M, Bradley A, Bonanno J, McNamara NA, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci 2009;50:3671-3679.
31. Yildiz EH, Fan VC, Banday H, Ramanathan LV, Bitra RK, Garry E, et al. Evaluation of a new tear osmometer for repeatability, using 0.5–µL (500-Nanoliter) samples. Cornea 2009;28:677-680.
32. Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010;51:6125-30.
33. Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res 2010;35:553-564.
34. Berta A, Higazy M, Petricek I. Red eye: Differential diagnosis and management. Int Ophthalmol 2008;28:1-64.
35. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-1496.
36. Moon JW, Lee HJ, Shin KC, Wee WR, Lee JH, Kim MK. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye. Korean J Ophthalmol 2007;21:189-194.
37. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 2008;27:64-69.
38. Smith J, Nichols KK, Baldwin EK. Current patterns in the use of diagnostic tests in dry eye evaluation. Cornea 2008;27:656-662.
39. Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf 2009;7:199-211.
40. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: Determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006;47:4309-4315.
41. Li DQ, Chen Z, Song XJ, Luo L, Pflugfelder SC. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004;45:4302-4311.
42. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006;82:588-596.
43. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:75-92.
44. Benelli U, Nardi M, Posarelli C, Albert TG. Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness. Cont Lens Anterior Eye 2010;33:61-67.

How to cite this article: Jadidi K, Panahi Y, Ebrahimi A, Mafi M, Nejat F, Sahebkar A. Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury. J Ophthalmic Vis Res 2014;9:417-22.

Source of Support: Baqiyatallah University of Medical Sciences. Conflict of Interest: Baqiyatallah University of Medical Sciences.